中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

交易中 12-19 14:21:20

3.240

+0.030

+0.93%

最高3.250	最低3.170	成交量1,816万
今开3.190	昨收3.210	日振幅2.49%
总市值608.84亿	流通市值608.84亿	总股本187.91亿
成交额5,836万	换手率0.10%	流通股本187.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":3.24,"timestamp":1734589266033,"preClose":3.21,"halted":0,"volume":18160425,"delay":0,"floatShares":18791217230,"shares":18791217230,"eps":0.13500509,"marketStatus":"交易中","marketStatusCode":2,"change":0.03,"latestTime":"12-19 14:21:20","open":3.19,"high":3.25,"low":3.17,"amount":58357317,"amplitude":0.024922,"askPrice":3.24,"askSize":41000,"bidPrice":3.23,"bidSize":1512000,"shortable":3,"etf":0,"ttmEps":0.23780389560037943,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734595800000},"adr":0,"adjPreClose":3.21,"dividendRate":0.018143,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.486025,"impliedVol":0.3064,"impliedVolPercentile":0.0486,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK"},"requestUrl":"/m/hq/s/01177/tweets","defaultTab":"tweets","newsList":[{"id":"2492198509","title":"交银国际：医保工作会议再提丙类目录和支持商保发展 关注政策宽松相关机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492198509?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:31","pubTimestamp":1734571909,"startTime":"0","endTime":"0","summary":"全国医疗保障工作会议首提探索形成丙类目录。全国医疗保障工作会议共提出八大工作重点，其中多项措施明确支持商保发展。其中第五条“强化医保战略购买，赋能医药产业创新发展”指出，要“支持引导普惠型商业健康保险及时将创新药品纳入报销范围，研究探索形成丙类药品目录，并逐步扩大至其他符合条件的商业健康保险”。预计2025年，商保将有望迎来进一步发展，为解决创新药上市后的支付问题提供新的思路。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1515","BK1521","LU1794554557.SGD","BK1583","LU0417516571.SGD","09926","IE00BPRC5H50.USD","01952","BK1191","LU2488822045.USD","LU0348783233.USD","BK1147","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1589","BK1161","LU1720050803.USD","LU0348784397.USD","01177","BK1574","03329"],"gpt_icon":0},{"id":"2492891167","title":"【券商聚焦】交银国际预计2025年商保将有望进一步发展 协助解决创新药支付问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2492891167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492891167?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:59","pubTimestamp":1734569982,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际预计2025年商保将有望进一步发展，协助解决创新药支付问题。同时，丙类目录+商保差异化发展的创新支付机制或缓解创新药械企业面临的进院难、报销支付难问题。近期医药板块在大幅震荡后有所回落，考虑到板块估值仍处于历史底部、叠加后续财政、医保/商保利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1589","LU0417516571.SGD","LU1720050803.USD","IE00B543WZ88.USD","09926","01177","BK1515","BK1521","159992","02096","06978","01952","BK1583","LU1794554557.SGD","BK1191","LU0348783233.USD","BK1147","LU0348784397.USD","BK1161","03329","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2492644271","title":"【湾区早参】香港推动黄金市场发展工作小组正式成立；深圳每年发放最高5亿元“训力券”","url":"https://stock-news.laohu8.com/highlight/detail?id=2492644271","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492644271?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:37","pubTimestamp":1734568677,"startTime":"0","endTime":"0","summary":"措施提出，发放“训力券”。每年发放最高5亿元“训力券”，降低人工智能模型研发和训练成本。于公告日期，公司正与潜在独立投资者磋商可能发行及认购可换股债券，预期本金总额5亿美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949913","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01899","SG9999014674.SGD","BK1110","BK1589","BK1610","PFS","01177","BK1515","BK1521","BK4017","CDE","BK1240","BK1554","01907","03800","01862","BK4211","BK1191","BK1147","BK1169","BK1594","BK4195","BK1139","00804"],"gpt_icon":0},{"id":"2492901547","title":"中国生物制药创新药III期研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492901547","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492901547?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:01","pubTimestamp":1734519698,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412183272216750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272216750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","06978","BK1191","01177","BK1574","BK1589","III","BK1161","BK4134","BK1521"],"gpt_icon":0},{"id":"2492597703","title":"中国生物制药创新药研究获阳性结果 申请上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2492597703","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492597703?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:23","pubTimestamp":1734513797,"startTime":"0","endTime":"0","summary":"财中社12月18日电中国生物制药（01177）发布公告，宣布其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272169369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","01177","BK1521","BK1161","BK1515","06978","BK1191","BK1574"],"gpt_icon":0},{"id":"2492972491","title":"中生制药(01177.HK)非小细胞肺癌放化疗后巩固治疗药物III期研究取得阳性结果  将就适应症提上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2492972491","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492972491?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:05","pubTimestamp":1734512700,"startTime":"0","endTime":"0","summary":"集团已与中国国家药品监督管理局药品审评中心就该适应症的上市申请进行沟通，并获得CDE书面同意提交上市申请。集团将于近期递交上市申请。同步/序贯放化疗后未进展的、局部晚期/不可切除的NSCLC的巩固治疗是安罗替尼即将申报上市的第11个适应症、贝莫苏拜单抗即将申报上市的第4个适应症。(港股报价延迟最少十五分钟。沽空资料截至 2024-12-18 16:25。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","01477","BK1589","BK1191","BK1521","BK1515","BK1574"],"gpt_icon":0},{"id":"2492972512","title":"中国生物制药(01177)：贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊用于非小细胞肺癌放化疗后巩固治疗III期研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492972512","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492972512?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:04","pubTimestamp":1734512647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊作为巩固治疗在同步╱序贯放化疗后未进展的、局部晚期╱不可切除的非小细胞肺癌患者中的III期临床研究 已完成方案预设的期中分析，独立数据监查委员会判定主要研究终点无进展生存期达到方案预设的优效界值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","BK1191","BK1521","BK4134","BK1589","III","BK1515"],"gpt_icon":0},{"id":"2492941582","title":"创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2492941582","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492941582?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:55","pubTimestamp":1734486946,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念多数上扬，圣诺医药 涨11.56%，百奥赛图涨9.68%，歌礼制药涨7.98%，绿竹生物涨4.73%，再鼎医药涨4.41%，康诺亚涨1.34%，中国生物制药涨0.95%，信达生物涨0.69%银河证券表示，1）医药创新是医药增长的核心动力。对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949850","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1574","BK1191","02480","BK1583","02257","LU2488822045.USD","06978","159938","BK1515","BK1588","01177","02315","BK1161","LU2328871848.SGD","01672","159992","09939","01801","BK1587","09688","BK1589","LU1969619763.USD","BK1521"],"gpt_icon":0},{"id":"2492496669","title":"南向资金12月17日净买入中国生物制药938.30万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492496669","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492496669?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:30","pubTimestamp":1734485416,"startTime":"0","endTime":"0","summary":"12月17日, 南向资金增持中国生物制药938.30万股，连续5日增持。截止当日收盘，港股通共持有中国生物制药221488.53万股，占流通股11.77%。中国生物制药近5个交易日下跌4.80%，港股通累计增持6152.05万股；近20个交易日下跌3.06%，港股通累计增持15613.89万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218093356ab807d42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218093356ab807d42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1589","BK1515","BK1191","01177"],"gpt_icon":0},{"id":"2492498545","title":"【券商聚焦】国证国际：创新药企和医疗器械公司有望通过出海不断打开市场天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2492498545","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492498545?lang=zh_cn&edition=full","pubTime":"2024-12-17 14:20","pubTimestamp":1734416402,"startTime":"0","endTime":"0","summary":"对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。由于中美定价差异大，企业可通过license out不断打开市场天花板。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949796","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1181","LU1969619763.USD","159992","BK1161","02162","BK1515","01801","01177","BK1191","06978","159883","BK1222","BK1100","BK1589","BK1583","BK1521","LU2328871848.SGD","LU2488822045.USD","09996","09997","BK1587","06880","BK1574"],"gpt_icon":0},{"id":"2491655474","title":"美银证券：维持中国生物制药“买入”评级 目标价上调至181港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491655474","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491655474?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:53","pubTimestamp":1734335580,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　美银证券发布研究报告称，基于中国生物制药（01177）最新经营数据，将2024至2026年收入预测轻微上调0.1%、0.2%及0.2%，至290.52亿、318.16亿及347.22亿元人民币，今年每股盈利预测亦从0.11元人民币调升至0.2元人民币。考虑到其销售表现强劲，以及产品管道研发进展良好，美银将中生制药的目标价从3.8港元上调至4港元，重申“买入”评级。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-12-16/doc-inczrvkr5866030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","01177"],"gpt_icon":0},{"id":"2491063147","title":"美银证券：维持中国生物制药(01177)“买入”评级 目标价上调至181港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491063147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491063147?lang=zh_cn&edition=full","pubTime":"2024-12-16 13:42","pubTimestamp":1734327761,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研究报告称，基于中国生物制药(01177)最新经营数据，将2024至2026年收入预测轻微上调0.1%、0.2%及0.2%，至290.52亿、318.16亿及347.22亿元人民币，今年每股盈利预测亦从0.11元人民币调升至0.2元人民币。考虑到其销售表现强劲，以及产品管道研发进展良好，美银将中生制药的目标价从3.8港元上调至4港元，重申“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","01177"],"gpt_icon":0},{"id":"2491681434","title":"中国生物制药(01177)出现大手卖出110万股，成交价$3.25，涉资357.5万","url":"https://stock-news.laohu8.com/highlight/detail?id=2491681434","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491681434?lang=zh_cn&edition=full","pubTime":"2024-12-16 10:00","pubTimestamp":1734314400,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午10:00出现大手卖出，成交量为110万，成交价为港币$3.25，涉资357.5万。至目前为止，股价跌1.212%，今日最高价为$3.33，而最低价为$3.25，总成交量为1.029千万股，总成交金额港币$3.373千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2412164367/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1521","BK1515","01177","BK1589"],"gpt_icon":0},{"id":"2491668618","title":"南向资金12月13日净买入中国生物制药2320.20万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2491668618","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491668618?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312613,"startTime":"0","endTime":"0","summary":"12月13日, 南向资金增持中国生物制药2320.20万股，连续3日增持。截止当日收盘，港股通共持有中国生物制药219489.78万股，占流通股11.67%。中国生物制药近5个交易日上涨0.61%，港股通累计增持4688.32万股；近20个交易日下跌0.30%，港股通累计增持15566.04万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093123ab7af933&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093123ab7af933&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1521","BK1191","BK1589","01177"],"gpt_icon":0},{"id":"2491520347","title":"医药行业周报：第十批国采竞争相对激烈 中标品种集中度再度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2491520347","media":"平安证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491520347?lang=zh_cn&edition=full","pubTime":"2024-12-15 00:00","pubTimestamp":1734192000,"startTime":"0","endTime":"0","summary":"第十批国采竞争相对激烈，中标品种集中度再度提升12月12日晚，上海阳光医药采购网发布第十批国采拟中选结果。我们发现，相比于第八批和第九批国采中标品种19%和18%相对较低的集中度，在第十批集采相对竞争激烈的压力下，中标品种集中度提升至24%，接近十批国采合计26%的集中度水平，但尚不及第五批集采32%的集中度水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241215202501a1f06e8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241215202501a1f06e8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","02196","01177"],"gpt_icon":0},{"id":"2491343545","title":"中国生物制药12月13日主力资金流入1456万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491343545","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491343545?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:15","pubTimestamp":1734077752,"startTime":"0","endTime":"0","summary":"12月13日, 中国生物制药股价跌2.65%，报收3.30元，成交金额1.84亿元，换手率0.30%，振幅2.65%，量比0.90。中国生物制药今日主力资金净流入1456万元，连续3日净流入，上一交易日主力净流入1064万元，今日环比增加36.84%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为29.41%，平均涨幅为2.57%。该股近5个交易日上涨1.52%，主力资金累计净流入3727万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入7966万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161619a1eb693c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161619a1eb693c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","BK1515","BK1589","BK1521"],"gpt_icon":0},{"id":"2491934354","title":"浩欧博：实际控制人变更为中国生物制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2491934354","media":"格隆汇资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491934354?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:15","pubTimestamp":1734077729,"startTime":"0","endTime":"0","summary":"本次股份转让完成及表决权放弃后，辉煌润康持有公司18,670,878股股份及该等股份对应的表决权，占剔除回购专用账户中股份数量后浩欧博股份总数的29.99%，浩欧博原实际控制人JOHNLI、WEIJUNLI、陈涛通过海瑞祥天、苏州外润和直接持股合计控制剔除回购专用账户中股份数量后浩欧博16.17%的表决权。公司控股股东由海瑞祥天变更为辉煌润康，公司实际控制人由JOHNLI、WEIJUNLI、陈涛变更为中国生物制药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161541ab74bfa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161541ab74bfa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01177","BK1589","BK1191","BK1521"],"gpt_icon":0},{"id":"2491348044","title":"浩欧博(688656.SH)控股股东变更为辉煌润康 实控人变更为中国生物制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2491348044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491348044?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:15","pubTimestamp":1734077714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博 发布公告，公司于2024年12月13日收到控股股东海瑞祥天生物科技(集团)有限公司的通知，获悉其协议转让公司股份事宜已完成过户登记手续。公司控股股东由海瑞祥天变更为辉煌润康，公司实际控制人由JOHN LI、WEIJUN LI、陈涛变更为中国生物制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","01177","BK1521","688656","BK1589","BK0239"],"gpt_icon":0},{"id":"2491639229","title":"中国生物制药(01177)出现大手买入90.5万股，成交价$3.29，涉资297.745万","url":"https://stock-news.laohu8.com/highlight/detail?id=2491639229","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491639229?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:31","pubTimestamp":1734060660,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午11:31出现大手买入，成交量为90.5万，成交价为港币$3.29，涉资297.745万。至目前为止，股价跌2.95%，今日最高价为$3.37，而最低价为$3.28，总成交量为2.572千万股，总成交金额港币$8.522千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2412136001/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1191","BK1521","BK1589","01177"],"gpt_icon":0},{"id":"2490831842","title":"交银国际：予内地医药行业“领先”评级 上海设百亿人民币并购基金有利加速行业整合","url":"https://stock-news.laohu8.com/highlight/detail?id=2490831842","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490831842?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:20","pubTimestamp":1733970040,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研究报告称，予内地医药行业“领先”评级。上海市发布文件，提出设立100亿元人民币生物医药产业并购基金，以推动行业的创新发展和并购重组，该行认为有利于加速行业的整合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","09926","02096","01952"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0446},{"period":"1month","weight":-0.0302},{"period":"3month","weight":-0.0273},{"period":"6month","weight":0.2466},{"period":"1year","weight":0.0497},{"period":"ytd","weight":-0.0562}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.010558},{"month":2,"riseRate":0.666667,"avgChangeRate":0.059128},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044408},{"month":4,"riseRate":0.47619,"avgChangeRate":0.024679},{"month":5,"riseRate":0.714286,"avgChangeRate":0.038695},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000979},{"month":7,"riseRate":0.619048,"avgChangeRate":0.029709},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.01409},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.016432},{"month":10,"riseRate":0.571429,"avgChangeRate":0.033241},{"month":11,"riseRate":0.52381,"avgChangeRate":0.069716},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.007079}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}